FDA Awards Priority Review Voucher for AVLAYAH
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
FDA has awarded a priority review voucher to Denali Therapeutics for AVLAYAH, a treatment for neurologic manifestations of Hunter syndrome in certain pediatric patients. The notice confirms that the product met the rare pediatric disease program criteria after its approval on March 24, 2026. The practical effect is mainly for Denali and the pharmaceutical sector. The voucher can be used to speed FDA review of a future drug application, or potentially transferred, making it a valuable regulatory asset. No new compliance duties are created for healthcare providers or patients.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- FDA confirms that AVLAYAH qualifies for a rare pediatric disease priority review voucher.
- Denali Therapeutics receives the voucher as the product sponsor and manufacturer.
- The notice identifies AVLAYAH’s approved pediatric Hunter syndrome indication.